摘要
目的分析甲状腺癌患者不同治疗方法的生存时间及影响因素,以期为甲状腺癌治疗提供依据及建议。方法采用随访研究分析1992年1月至2005年12月收治的分化型甲状腺癌患者的生存资料,对其年龄、性别、婚姻状况、医疗保险方式、职业、文化程度、生育等情况进行统计分析。结果生存时间单因素分析结果显示,综合治疗组(119.4月)与单纯治疗组(109.7月)患者的平均生存时间差异有统计学意义(t=2.138,P=0.033);同时生存时间在不同临床分期、不同职业、不同文化程度、不同医保情况之间差异也有统计学意义(P<0.05);但尚未发现不同婚姻状况、不同性别之间的生存时间差异有统计学意义(P>0.05)。结论手术+131I+TSH抑制治疗的综合治疗组患者平均生存时间大于手术+TSH抑制治疗的单纯治疗组患者平均生存时间,尤其在第Ⅳ期患者中,两组中位生存时间的差异更显著;临床分期、职业、文化程度、医保情况对患者的生存时间也有影响。
Objective To analyze the effects of different treatment methods on survival time of patients with thyroid cancer in order to provide the basis and recommendations for the treatment of thyroid cancer. Methods A follow-up study was conducted to analyze the survival data of patients with differentiated thyroid cancers from January 1992 to December 2005. The study information included patients＇ features, such as age, gender, employment status, medical insurance and marital status. Results Univariate survival analysis showed that the survival time of the combined therapy group and the simple treatment group was statistically significant （ P 〈 0.05 ）; survival time in different clinical stages, different occupations, different degree of education, and different health insurance was statistically significant （ P 〈 0.05 ）. There was no statistically different between marital status, gender and survival time （ P 〉 0.05 ）. Conclusion The average survival time of patients with surgery, 131I and TSH suppression therapy is greater than that with the surgery combined and TSH inhibited therapy, especially in the stage 1V patients. Clinical stage, occupation, education, health care are the determinants for the survival time, too.
出处
《标记免疫分析与临床》
CAS
2014年第1期63-67,共5页
Labeled Immunoassays and Clinical Medicine
